Product
BMN 111
Aliases
Modified recombinant human C-type natriuretic peptide, Vosoritide
Name
VOXZOGO 0.4mg
INN Name
vosoritide
FDA Approved
Yes
5 clinical trials
1 organization
1 indication
1 document
Indication
AchondroplasiaClinical trial
A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With AchondroplasiaStatus: Active (not recruiting), Estimated PCD: 2031-06-01
Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 MonthsStatus: Completed, Estimated PCD: 2022-01-26
Clinical trial
A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With AchondroplasiaStatus: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With AchondroplasiaStatus: Active (not recruiting), Estimated PCD: 2027-12-01
Clinical trial
A Phase 1, Randomized, Open-Label, Sponsor-Open, Two-Sequence, Two-Period Crossover Study to Investigate the Bioequivalence of a Single Subcutaneous Dose of BMN 111 Administered Using Either a Vial and Syringe or Injector Pen in Healthy Adult ParticipantsStatus: Terminated, Estimated PCD: 2023-06-14
Document
DailyMed Label: VOXZOGO 0.4mgOrganization
BioMarin Pharmaceutical Inc.